The Study
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
This study is like a fair test where half the people got a new medicine and half got a sugar pill, and nobody knew who got what. The people who got the medicine lost a lot of fat and gained muscle — so we can say the medicine probably caused those changes. But we can't say it will work the same for everyone, because only 75 people were tested.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested a new drug called bimagrumab in people with type 2 diabetes and extra body fat. The drug blocks a signal that normally limits muscle growth and may also help burn fat.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 574 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Losing fat while gaining muscle is rare—most diets make you lose both.
- 2This drug did both at once, and lowered blood sugar as much as some diabetes medicines, even without changing other meds.
- 3People who got the drug lost 20.5% of their body fat, gained 3.6% more muscle, lost 6.5% of their total weight, and lowered their blood sugar (HbA1c) by 0.76% more than those who got a placebo.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
JAMA Network Open
Year
2021
Authors
S. Heymsfield, L. Coleman, Ram R Miller, D. Rooks, D. Laurent, O. Pétricoul, J. Praestgaard, Therese Swan, Thomas Wade, Robert G. Perry, B. Goodpaster, R. Roubenoff
Related Content
Claims (6)
Bimagrumab, a specific antibody, decreases body fat without requiring the presence or activity of GLP-1 receptor agonists.
During weight loss, bimagrumab leads to an increase in lean mass, while apitegromab slows the loss of lean mass.
In adults with type 2 diabetes and obesity, taking bimagrumab for 48 weeks lowers HbA1c by 0.76 percentage points more than a placebo, even when background diabetes medications do not change.
In adults with type 2 diabetes and obesity, a drug called bimagrumab reduces waist size by 9.0 centimeters more than a placebo after 48 weeks, and this reduction is specifically due to loss of visceral fat in the abdomen.
In adults with type 2 diabetes and obesity, monthly intravenous injections of bimagrumab for 48 weeks reduce total body fat by 20.5%, increase lean mass by 3.6%, and lower overall body weight by 6.5%.
In adults with type 2 diabetes and obesity, bimagrumab increases lean body mass by 3.6% and decreases fat mass, whereas most weight-loss treatments reduce both fat and lean mass.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.